Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROC-101 in PAH and ILD-PH
NCT07175038Phase 2Recruiting
- Sponsor
- AllRock Bio
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ROC-101 in pulmonary arterial hypertension (PAH), Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by AllRock Bio. Started Oct 2025; status: recruiting.
02
Drugs
ROC-101
03
Conditions
pulmonary arterial hypertension (PAH)Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT07175038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175038.